ORNBV Orion Oyj Class B

Orion publishes Interim Report for January–September 2025 and holds a webcast on 28 October 2025

Orion publishes Interim Report for January–September 2025 and holds a webcast on 28 October 2025

ORION CORPORATION

PRESS RELEASE

14 OCTOBER 2025 at 11.15 EEST          

        

Orion publishes Interim Report for January–September 2025 and holds a webcast on 28 October 2025

Orion will publish Interim Report for January–September 2025 on Tuesday, 28 October 2025 at approximately 12.00 noon EET. The release and related presentation material will be available on the company’s website at after publishing.

Webcast and conference call

A webcast and a conference call for analysts, investors and media representatives will be held on Tuesday, 28 October 2025 at 13.30 EET.

A link to the live webcast is available on Orion's website at . A recording of the event will be available on the website later the same day.

Confenrence call can be joined by registering through the following link: .

Phone numbers and the conference ID to access the conference will be provided after the registration. In case you would like to ask a question during the conference, please dial *5 on your telephone keypad to enter the question queue.

Questions can also be presented in writing through the question form of the webcast.

Silent period

The silent period preceding the publication is ongoing and continues until the disclosure.

                                                 

Contact person:

Tuukka Hirvonen, Investor Relations, Orion Corporation

tel. +358 10 426 2721 

Publisher:

Orion Corporation

Communications

Orionintie 1A, FI-02200 Espoo, Finland



Orion is a globally operating Nordic pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. In 2024 Orion's net sales amounted to EUR 1,542 million and the company employed about 3,700 professionals worldwide, dedicated to building well-being. Orion's A and B shares are listed on Nasdaq Helsinki.



EN
14/10/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Orion Oyj Class B

 PRESS RELEASE

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securi...

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS5 MARCH 2026 at 15.00 EET          Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion Corporation has received a disclosure under Chapter 9, Section 5 of the Securities Market Act, according to which the total number of Orion shares owned directly and indirectly by BlackRock, Inc. and its funds decreased on 4 March 2026 below five (5) per cent of Orion C...

 PRESS RELEASE

Orion Oyj: Arvopaperimarkkinalain 9. luvun 10. pykälän mukainen ilmoit...

Orion Oyj: Arvopaperimarkkinalain 9. luvun 10. pykälän mukainen ilmoitus (BlackRock, Inc.) ORION OYJ        PÖRSSITIEDOTE / SUURIMMAT OSAKKEENOMISTAJAT -TIEDOTE        5.3.2026 KLO 15.00          Orion Oyj: Arvopaperimarkkinalain 9. luvun 10. pykälän mukainen ilmoitus (BlackRock, Inc.) Orion Oyj on saanut Arvopaperimarkkinalain 9. luvun 5 §:n mukaisen ilmoituksen, jonka mukaan BlackRock, Inc.:n ja sen rahastojen suoraan ja välillisesti omistamien Orionin osakkeiden osuus on 4.3.2026 alittanut viisi (5) prosenttia Orion Oyj:n kaikista osakkeista. BlackRock, Inc.:n ja sen rahastojen osu...

 PRESS RELEASE

Orion Group Financial Statement documents 2025 and Remuneration Report...

Orion Group Financial Statement documents 2025 and Remuneration Report published ORION CORPORATION STOCK EXCHANGE RELEASE – ANNUAL FINANCIAL REPORT 27 FEBRUARY 2026 at 11.05 EET         Orion Group Financial Statement documents 2025 and Remuneration Report published Orion Group's Financial Statement documents for 2025 have been published. The documents are available in Finnish and English on the Company's website at and are attached to this release. Financial Statement documents include the company’s Financial Statements, the Report by the Board of Directors, the Sustainability Stateme...

 PRESS RELEASE

Orion-konsernin tilinpäätösasiakirjat 2025 sekä palkitsemisraportti ju...

Orion-konsernin tilinpäätösasiakirjat 2025 sekä palkitsemisraportti julkaistu ORION OYJ        PÖRSSITIEDOTE – TILINPÄÄTÖS JA TOIMINTAKERTOMUS        27.2.2026 KLO 11.05         Orion-konsernin tilinpäätösasiakirjat 2025 sekä palkitsemisraportti julkaistu Orion-konsernin vuoden 2025 tilinpäätösasiakirjat on julkaistu suomeksi ja englanniksi yhtiön verkkosivuilla osoitteessa sekä tämän tiedotteen liitteinä. Tilinpäätösasiakirjat-dokumentti sisältää yhtiön tilinpäätöksen, toimintakertomuksen, kestävyysselvityksen (osana toimintakertomusta) sekä selvityksen hallinto- ja ohjausjärj...

 PRESS RELEASE

The Board of Directors of Orion Corporation decided on a new plan peri...

The Board of Directors of Orion Corporation decided on a new plan period for the Long-term Incentive program for the company’s key persons ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE12 FEBRUARY 2026 at 13.12 EET         The Board of Directors of Orion Corporation decided on a new plan period for the Long-term Incentive program for the company’s key persons The Board of Directors of Orion Corporation decided on a new Long-term Incentive Program on February 25, 2025. The Long-term Incentive Program consists of annually laun...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch